Executive Summary
Deobligations alert reveals $4.34B in major contract obligations dominated by NASA's $2.95B Caltech/JPL award (68% of total), signaling stable space R&D funding through 2028 but neutral equity impact as nonprofit. Four bullish signals ($1.13B total) highlight reliable revenue for Elevance Health, Emergent BioSolutions, ElbitAmerica, and Pyramid Systems in health IT/pharma, surveillance, and HUD IT through 2026-2030. HHS contracts aggregate ~$1.19B with long-term outlays, underscoring healthcare services resilience amid execution risks from firm-fixed pricing and subawards.
Tracking the trend? Catch up on the prior Contract Deobligations Alert digest from March 22, 2026.
Investment Signals(3)
- Health IT and Pharma Revenue Locked In(HIGH)▲
$1.03B obligated to Elevance (CMS desktop), Emergent (VIGIV supply), with $515M outlayed signaling steady cash flows through 2027.
- Surveillance and Small Biz IT Upside(MEDIUM)▲
$204M future revenue potential for ElbitAmerica (DHS border surveillance from 2026) and Pyramid Systems (GSA/HUD IT to 2026), with options adding $4M.
- NASA JPL Dominates but Nonprofit(HIGH)▲
$2.95B obligation (82% outlayed) for Caltech-managed space R&D through 2028 limits direct equity plays despite scale.
Risk Flags(3)
- Execution[HIGH RISK]▼
Firm-fixed-price and time-materials structures risk cost overruns on $632M Emergent/Elbit/Pyramid contracts with low/zero outlays to date.
- Regulatory[MEDIUM RISK]▼
Foreign ownership in $422M Emergent Canada and $105M ElbitAmerica exposes to DHS/HHS policy shifts on border security and biopharma supply.
- Execution[MEDIUM RISK]▼
Long tenures (avg. 8+ years to 2028) across all 7 contracts risk funding cuts or delays on $3.4B unoutlayed balance.
Opportunities(3)
- ◆
$250M+ unexercised options (e.g., $284M Emergent, $44M Icahn, $4M Pyramid) signal potential 10-60% obligation uplifts.
- ◆
HHS $1.19B focus on CMS/IT/vaccines through 2027 supports health services expansion amid nonprofit stability.
- ◆
Zero-outlay $204M Elbit/Pyramid contracts offer forward revenue visibility in DHS/GSA border/IT without current balance sheet drag.
Sector Themes(2)
- ◆
55% of value ($2.38B incl. Caltech proxy) in HHS/NASA health/space R&D with 60% avg. outlayed, favoring cost-plus stability.
- ◆
$105M DHS non-competed award highlights border tech priority despite foreign ownership.
Watch List(3)
- 👁
{"entity"=>"Emergent BioSolutions", "reason"=>"$422M HHS VIGIV with $284M options and $256M outlayed signals biopharma revenue ramp to 2029.", "trigger"=>"Option exercise or extension beyond 2027"}
- 👁
{"entity"=>"ElbitAmerica", "reason"=>"$105M DHS surveillance starting 2026 with zero outlay offers pure future growth in border security.", "trigger"=>"Initial outlays or 2030 extension award"}
- 👁
{"entity"=>"Pyramid Systems", "reason"=>"Small/woman-owned $100M GSA IT set-aside to 2026 positions for HUD follow-ons.", "trigger"=>"Outlay start or new small biz wins >$50M"}
Get daily alerts with 3 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 7 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
Contract Option Exercises — March 24, 2026
Contract Option Exercises
March 24, 2026
NASA & Space Contracts Intelligence — March 24, 2026
NASA & Space Contracts Intelligence
March 24, 2026
All HHS Contracts — March 24, 2026
All HHS Contracts